Peptide · Vial
BPC 157
$8910mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
EternaGen / Research use onlyPeptide · Research use only
Retatrutide
From CA$149CAD
An experimental compound designed to act on three metabolic hormone receptors at the same time.
Available to approved purchasers
Select strength
1
Documentation review pending Fulfilled in Canada Research use only
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
Retatrutide, clearly explained.
An experimental compound designed to act on three metabolic hormone receptors at the same time.
Overview
Retatrutide has reached phase 3 clinical research for weight and blood-sugar outcomes, but it remains investigational and is not approved for public use. Trial findings apply to the sponsor’s controlled product—not a separately sourced material.
Retatrutide is a single investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. It remains under clinical development and is not an approved public-use medicine as of this review.- Format
- Vial
- Available strengths
- 10mg · 20mg · 30mg · 40mg
- Documentation
- Source review pending
Research at a glancePhase 2 and emerging phase 3 human evidence; still investigational
Reviewed 23 July 2026View research context Specifications
Product details
- Storage and handling
- Follow the batch-specific conditions included with the product documentation.
Batch documentationSource review pending
Not yet publishedSupplier-origin documentation will be published only after EternaGen verifies the source and record details.
Important research-use boundary
Retatrutide remains investigational. FDA states it has not been found safe and effective for any condition and cannot be used in compounding under U.S. federal law; Health Canada lists unauthorized injectable retatrutide among products consumers should not buy or use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Obesity and overweight
Phase 2 and phase 3 programmes study body-weight change and related outcomes under controlled escalation schedules.
Evidence so far: Human randomized trialsQuestion 02
Type 2 diabetes
A 2026 phase 3 trial reported HbA1c and body-weight outcomes over 40 weeks in adults inadequately controlled by diet and exercise.
Evidence so far: Published phase 3 evidenceQuestion 03
Safety and tolerability
Trials report gastrointestinal events and other dose-related observations; longer-term outcomes remain under study.
Evidence so far: Evolving clinical safety databaseProposed mechanism
How researchers are investigating the mechanism.
The molecule combines incretin-receptor signalling with glucagon-receptor activity. Clinical trials assess the net effect on glycaemia, appetite-related outcomes, body weight and safety rather than assuming each receptor contributes independently.
Evidence gaps
What remains unknown?
- Regulatory review is not complete, and no public-use retatrutide product has been approved.
- Long-term cardiovascular, pancreatic, gallbladder and other safety questions require the complete development programme and regulatory review.
- FDA states retatrutide cannot be used in compounding under U.S. federal law.
Primary sources
Check the original sources.
- Primary phase 2 studyJastreboff et al. Retatrutide for obesity, randomized phase 2 trial. N Engl J Med. 2023. PMID 37366315.
- Primary phase 3 studyBajaj et al. TRANSCEND-T2D-1 randomized phase 3 trial. Lancet. 2026. PMID 42250575.
- Current regulatory warningU.S. FDA. Concerns with unapproved GLP-1 drugs used for weight loss; retatrutide section. 2026.
Related products
Continue comparing.
Peptide · Vial
GHK-CU
From CA$54.9950mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Peptide · Pen
MOTS-c
From CA$6410mg20mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.